Breaking News Instant updates and real-time market news.

TPR

Tapestry

$30.78

-0.56 (-1.79%)

, REGN

Regeneron

$304.81

-4.69 (-1.52%)

08:01
05/18/19
05/18
08:01
05/18/19
08:01

Regeneron, Tapestry among cheap stocks to ride out trade war, Barron's says

Applied Materials (AMAT), BorgWarner (BWA), Charles Schwab (SCHW), Regeneron Pharmaceuticals (REGN) and Tapestry (TPR) among recently sold-off stocks that, relative to earnings, are cheaper than both the market and their own five-year averages, and with growth opportunity that appears brighter than gloomy valuations suggest, Jack Hough writes in this week's edition of Barron's. Reference Link

TPR

Tapestry

$30.78

-0.56 (-1.79%)

REGN

Regeneron

$304.81

-4.69 (-1.52%)

SCHW

Charles Schwab

$43.21

-0.94 (-2.13%)

BWA

BorgWarner

$36.27

-0.375 (-1.02%)

AMAT

Applied Materials

$42.72

-1.56 (-3.52%)

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 26

    Jun

  • 25

    Jul

TPR Tapestry
$30.78

-0.56 (-1.79%)

05/06/19
PIPR
05/06/19
NO CHANGE
Target $39
PIPR
Overweight
Tapestry shares near 'trough multiples' with 4% yield, says Piper Jaffray
Piper Jaffray analyst Erinn Murphy says investor sentiment on Tapestry is negative and that while she does have "emerging questions on the multi-year positioning of the accessible luxury category," the shares are near "trough multiples" with a dividend yield of greater than 4%. She believes Tapestry will maintain positive double-digit earnings growth for fiscal 2020 and keeps an Overweight rating on the shares with a $39 price target. Further, Murphy thinks the company's fiscal Q3 results will be in-line with estimates.
05/06/19
BARD
05/06/19
NO CHANGE
Target $43
BARD
Outperform
Tapestry facing 'tricky setup' ahead of earnings, says Baird
Baird analyst Mark Altschwager said he sees Tapestry facing a "tricky setup" ahead of its earnings report, stating that the company's conservative guidance is offset by risk to Q3 comp sales and gross margin estimates, especially at the Kate Spade brand. However, he also believes a lot of negativity is already priced in and continue to see an attractive risk/reward for investors who are "willing to let the story play out" over the next six to twelve months. Altschwager keeps an Outperform rating and $43 price target on Tapestry shares.
04/23/19
04/23/19
DOWNGRADE

Mixed
Tapestry downgraded to Mixed following checks at OTR Global
As previously reported, OTR Global downgraded Tapestry to Mixed from Positive. The firm's checks indicate Q3 outlet sales and traffic were hurt by the late Easter and cold spring.
05/09/19
STPT
05/09/19
UPGRADE
STPT
Buy
Tapestry upgraded to Buy from Hold at Standpoint Research
REGN Regeneron
$304.81

-4.69 (-1.52%)

05/13/19
CANT
05/13/19
NO CHANGE
Target $405
CANT
Neutral
Regeneron price target lowered to $405 from $441 at Cantor Fitzgerald
Cantor Fitzgerald analyst Regeneron Pharmaceuticals (REGN) to $405 from $441 saying the company's expenses are tracking higher than his projections. Further, he thinks investor concerns about Novartis' (NVS) brolucizumab approval in eye and increased atopic dermatitis competition remain headwinds for share upside. The analyst reiterates a Neutral rating on Regeneron following its Q1 results.
05/16/19
JPMS
05/16/19
NO CHANGE
Target $395
JPMS
Neutral
Regeneron selloff brings improved risk/reward, says JPMorgan
JPMorgan analyst Cory Kasimov keeps a Neutral rating on shares of Regeneron Pharmaceuticals buy says the stock's risk/reward is improved following the recent sharp pullback. The analyst adds that feedback from five doctors supports his above-consensus estimates for Dupixent. Kasimov currently models peak sales north of $7B across atopic dermatitis, asthma, and nasal polyps in the U.S. and Europe, "with everything else left as upside." Every $1B in total Dupixent revenue results in a $20 impact to the stock's fair valuation, the analyst tells investors in a research note titled "Dupi...How Big Is Big?"
05/08/19
BMOC
05/08/19
NO CHANGE
Target $375
BMOC
Market Perform
Regeneron price target lowered to $375 from $412 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron (REGN) to $375 after its "uninspiring" Q1 driven by higher R&D costs and lower collaboration revenue with Sanofi (SNY). The analyst notes that while the company's Dupixent is "showing progress" and Eylea's 8% revenue growth is a positive, he is also concerned with higher discounting for the latter along with the potential for a more competitive vascular endothelial growth factor, or VEGF, landscape. Luchini keeps his Market Perform rating on Regeneron.
05/08/19
ADAM
05/08/19
NO CHANGE
Target $353
ADAM
Hold
Regeneron price target cut to $353 from $408 at Canaccord
Canaccord analyst John Newman cut his price target for Regeneron to $353 from $408 and maintained a Hold rating following the company's Q1 results, saying R&D expense and 2019 guidance surprised investors, although he thinks more R&D investment is beneficial in the long-term, despite short-term pains. However, the increase in R&D spending may persist due to ongoing early pipeline programs, Libtayo development costs, higher clinical manufacturing costs, and higher headcount, Newman tells investors in a research note.
SCHW Charles Schwab
$43.21

-0.94 (-2.13%)

02/20/19
02/20/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CVS Health (CVS) downgraded to Market Perform from Outperform at Wells Fargo with analyst Peter Costa citing its "continued failure" to stabilize its existing businesses, particularly the long-term care business, after two years of pressure. 2. Southwest (LUV) downgraded to Sell from Neutral at Goldman Sachs with analyst Catherine O'Brien saying Southwest's fiscal 2019 pretax margin will decline 60 basis points due to the dilutive impact of its new Hawaii flying and unit cost ex-fuel pressures. 3. Charles Schwab (SCHW) downgraded to Sell from Neutral at UBS, while E-Trade (ETFC) was downgraded to Neutral from Buy. 4. Palo Alto Networks (PANW) downgraded to Hold from Buy at Gabelli with analyst Hendi Susanto citing valuation. 5. Teva (TEVA) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying her investment thesis is "broken" after Teva's "disappointing 2019 guidance and cautious longer-term outlook." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/19
UBSW
02/20/19
DOWNGRADE
Target $42
UBSW
Sell
Charles Schwab downgraded to Sell from Neutral at UBS
UBS analyst Brennan Hawken downgraded Charles Schwab to Sell and lowered his price target for the shares to $42 from $48. The analyst sees revenue headwinds at the same time as risk to upward pressure on expenses. This will lead to earnings and multiple compression, Hawken tells investors in a research note. The analyst believes Schwab's revenue guidance, which assumes a mid-year rate hike and higher daily average revenue trades, is aggressive against the current backdrop. Expectations may be too high and could put the stock at risk, particularly since buybacks are likely not enough to "cushion the blow to the growth story," Hawken contends.
01/29/19
MSCO
01/29/19
NO CHANGE
MSCO
Overweight
Morgan Stanley sees 'more to come' from discount brokers after strong Q4
Morgan Stanley analyst Michael Cyprys said the "strong" Q4 earnings reports from Charles Schwab (SCHW), E-Trade (ETFC) and TD Ameritrade (AMTD) showed that the discount brokers can grow revenues in a volatile, late-cycle backdrop. He increased his 2020 top-line estimates across the group, citing expectations for higher net interest margins and higher cash balances. Cyprys, who said the valuations in the group remain compelling on both an absolute and relative basis, keeps Overweight ratings on all three stocks mentioned. He raised his price target on Charles Schwab to $57 from $55, on E-Trade to $62 from $61 and on TD Ameritrade to $64 from $59.
01/22/19
MSCO
01/22/19
NO CHANGE
Target $57
MSCO
Overweight
Charles Schwab target raised to $57 ahead of winter update at Morgan Stanley
Morgan Stanley analyst Michael Cyprys said he has increased conviction in Charles Schwab (SCHW) shares after the company saw stronger organic deposit growth and broadly strong underlying growth metrics in Q4. He expects Charles Schwab to provide2019 guidance at the company's upcoming Winter Update on February 5 that should meet consensus expectations, but he also expects Schwab to beat those expectations over the course of 2019, as they havve done in prior years. He also expects Charles Schwab to give "more rational" pricing commentary this late in the cycle, which should support the stock and peers TD Ameritrade (AMTD) and E-Trade (ETFC), Cyprys tells investors. He raised his price target on Charles Schwab shares to $57 from $55 ahead of the update call and keeps an Overweight rating on the stock.
BWA BorgWarner
$36.27

-0.375 (-1.02%)

01/07/19
MSCO
01/07/19
NO CHANGE
MSCO
Morgan Stanley sees most, if not all, auto suppliers guiding below consensus
Ahead of the Detroit auto show, Morgan Stanley analyst Armintas Sinkevicius said he expects that most, if not all, auto suppliers will provide 2019 guidance that is lower than consensus. He sees the most downside risk to Visteon (VC) and Adient (ADNT), estimating that they may guide adjusted EBITDA 6.4% and 5.0% below consensus, respectively. Not everyone will provide guidance at the show, as American Axle (AXL) and Delphi Technologies (DLPH) gave guidance with Q3 earnings and Aptiv (APTV) and BorgWarner (BWA) plan to wait for Q4 earnings, added Sinkevicius. He estimates that, on average, the auto suppliers will guide to 1.5% revenue growth and -25 bps of margin contraction in 2019, adding that his concern is that the guidance provided at Detroit may not sufficiently de-risk figures. Others in the space include Lear (LEA), Tenneco (TEN) and Magna (MGA).
02/15/19
BARD
02/15/19
NO CHANGE
Target $47
BARD
Outperform
BorgWarner price target raised to $47, remains top pick at Baird
Baird analyst David Leiker raised his price target on BorgWarner to $47 from $41 after the company reported in-line Q4 results. The analyst said it remains one of the best ideas on his list and noted valuation is currently near cycle lows. He sees improved near-term performance, significant re-rating potential given its valuation, and an attractive long-term growth profile. Leiker reiterated his Outperform rating on BorgWarner shares.
02/13/19
GHSC
02/13/19
INITIATION
GHSC
Neutral
BorgWarner initiated with a Neutral at Seaport Global
01/28/19
BMOC
01/28/19
NO CHANGE
BMOC
BorgWarner, Gentherm, Visteon, Autolive price targets raised at BMO Capital
BMO Capital analyst Richard Carlso is turning more bullish on the auto and mobility equipment industry, saying the sentiment from the most recent CES, Detroit Auto Show, and GM's (GM) Capital Markets Day events has shifted his outlook from "cautious" to "cautiously optimistic". The analyst attributes the snap-back rally in the sector stocks' prices to increased optimism over the impact of lingering trade issues and outlooks from companies that have so far updated on their Q4 performance, all of which suggested that the 2018-end declines were overextended. Carlson is raising his price target on Autoliv (ALV) to $84 from $79, on Gentex (GNTX) to $27 from $24, on Aptiv (APTV) to $84 from $74, on Veoneer (VNE) to $41 from $36, on BorgWarner (BWA) to $49 from $44, and on Visteon (VC) to $91 from $84.
AMAT Applied Materials
$42.72

-1.56 (-3.52%)

05/15/19
05/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Westlake Chemical (WLK) upgraded to Buy from Neutral at Goldman Sachs with analyst Robert Koort saying the stock's 49% decline over the past year has created an opportunity to gain exposure to two commodity cycles that are bottoming, ethylene and chloralkali. 2. Zillow (ZG, Z) upgraded to Buy from Neutral at Guggenheim with analyst Jake Fuller saying its recent results prove that demand for Offers "is real" and he expects the company's Offers business to surpass its ad business by Q4 and generate greater than $1B of revenue in its first full year. 3. Chevron (CVX) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Neil Mehta saying Chevron's cash flow profile has positively inflected with the production contribution and capital spending roll-off from the startup of both the Gorgon and Wheatstone LNG projects. 4. Hess Corp. (HES) upgraded to Equalweight from Underweight at Capital One with analyst Phillips Johnston saying he reviewed his model post Q1 earnings and "massively" overhauled his Guyana production estimates. 5. Applied Materials (AMAT) and Advanced Energy (AEIS) upgraded to Positive from Neutral at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/19
RILY
05/17/19
UPGRADE
Target $54
RILY
Buy
Applied Materials upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Craig Ellis upgraded Applied Materials to Buy from Neutral and raised his price target for the shares to $54 from $46. Signs of a recovery are starting to emerge following the company's better than expected fiscal Q2 results, Ellis tells investors in a research note.
05/17/19
CHLM
05/17/19
NO CHANGE
Target $50
CHLM
Buy
Applied Materials price target raised to $50 from $44 at Craig-Hallum
Craig-Hallum analyst Christian Schwab raised his price target for Applied Materials to $50 from $44 and maintained a Buy rating following the company's Q3 results, saying the company outlined an expected return to growth in 2020. Schwab tells investors in a research note that while specific timing and magnitude of a recovery still lacks visibility, he is encouraged that estimate cuts appear to be over.
05/17/19
COWN
05/17/19
NO CHANGE
Target $53
COWN
Outperform
Applied Materials price target raised to $53 from $47 at Cowen
Cowen analyst Krish Sankar raised his price target on Applied Materials to $53 from $47 after the company reported in-line results for the April-end quarter and gave "better than feared" guidance for the July-end quarter, citing stable Semis demand and a healthy Services business. He noted that management's tone remained unchanged from a quarter ago, signaling no incremental signs of deterioration in conditions despite the fact that demand visibility remains limited. Sankar keeps an Outperform rating on Applied Materials shares.

TODAY'S FREE FLY STORIES

SEDG

SolarEdge

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SolarEdge rating change  »

SolarEdge upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$17.09

0.64 (3.89%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
Sunrun rating change  »

Sunrun upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SunPower rating change  »

SunPower upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:32
06/17/19
06/17
18:32
06/17/19
18:32
Hot Stocks
Bluescope Steel cuts FY19 EBIT growth view to up 6% from up 10% »

BlueScope announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$147.54

-1.25 (-0.84%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Hot Stocks
International Flavors CEO: We have planned for Brexit and China is benign for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$57.63

-0.65 (-1.12%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Periodicals
Senator aims to bar Huawei from seeking damages in patent courts, Reuters says »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:12
06/17/19
06/17
18:12
06/17/19
18:12
Hot Stocks
Breaking Hot Stocks news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$39.00

1.46 (3.89%)

18:04
06/17/19
06/17
18:04
06/17/19
18:04
Hot Stocks
Dish launches OnTech Smart Services »

Dish announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.30

-0.06 (-0.19%)

18:03
06/17/19
06/17
18:03
06/17/19
18:03
Hot Stocks
AT&T wins 24 GHz spectrum following FCC Auction 102 »

AT&T is the winning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:02
06/17/19
06/17
18:02
06/17/19
18:02
Syndicate
Biohaven Pharmaceutical offers to sell $300M in common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$51.42

0.01 (0.02%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

18:01
06/17/19
06/17
18:01
06/17/19
18:01
Hot Stocks
Versum Materials shareholders approve merger with Merck KGaA »

Versum Materials (VSM)…

VSM

Versum Materials

$51.42

0.01 (0.02%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

VLO

Valero

$76.93

0.19 (0.25%)

18:00
06/17/19
06/17
18:00
06/17/19
18:00
Periodicals
Valero restarting Port Arthur, Texas refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

VLO

Valero

$76.93

0.19 (0.25%)

17:59
06/17/19
06/17
17:59
06/17/19
17:59
Periodicals
Valero restarting Meraux, Louisiana refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

17:44
06/17/19
06/17
17:44
06/17/19
17:44
Hot Stocks
MoneyGram spikes almost 140% after blockchain company Ripple investment »

Money transfer company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

JKS

JinkoSolar

$22.59

-2.08 (-8.43%)

17:37
06/17/19
06/17
17:37
06/17/19
17:37
Downgrade
JinkoSolar rating change  »

JinkoSolar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

FCEL

FuelCell

$0.33

-0.0231 (-6.56%)

17:26
06/17/19
06/17
17:26
06/17/19
17:26
Earnings
FuelCell reports Q2 ($2.06), consensus ($2.24) »

Reports Q2 revenue $9.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMTI

Rockwell Medical

$4.39

0.2 (4.77%)

17:25
06/17/19
06/17
17:25
06/17/19
17:25
Hot Stocks
Breaking Hot Stocks news story on Rockwell Medical »

Rockwell Medical down 21%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

VRS

Verso

$17.91

-0.24 (-1.32%)

17:21
06/17/19
06/17
17:21
06/17/19
17:21
Hot Stocks
Verso adopts limited duration stockholder rights plan »

Verso announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHVKF

China Vanke Co

$0.00

(0.00%)

17:19
06/17/19
06/17
17:19
06/17/19
17:19
Downgrade
China Vanke Co rating change  »

China Vanke Co downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$16.88

0.68 (4.20%)

17:17
06/17/19
06/17
17:17
06/17/19
17:17
Syndicate
Breaking Syndicate news story on Rocket Pharmaceuticals »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

BA

Boeing

$354.90

7.71 (2.22%)

, EADSY

Airbus

$0.00

(0.00%)

17:17
06/17/19
06/17
17:17
06/17/19
17:17
Periodicals
Boeing gets zero new plane orders at Paris Air Show so far, CNBC says »

According to CNBC's…

BA

Boeing

$354.90

7.71 (2.22%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

17:17
06/17/19
06/17
17:17
06/17/19
17:17
Syndicate
Breaking Syndicate news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MELR

Melrose Bancorp

$18.40

-0.1 (-0.54%)

17:14
06/17/19
06/17
17:14
06/17/19
17:14
Hot Stocks
Breaking Hot Stocks news story on Melrose Bancorp »

Melrose Bancorp trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$55.40

0.66 (1.21%)

17:13
06/17/19
06/17
17:13
06/17/19
17:13
Hot Stocks
Cisco awarded maximum $724.1M Defense Information Systems Agency contract »

Cisco has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 16

    Jul

  • 14

    Aug

NI

NiSource

$29.16

0.41 (1.43%)

17:10
06/17/19
06/17
17:10
06/17/19
17:10
Periodicals
NiSource plans sale of unit tied to gas explosions, Bloomberg says »

According to a story from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.